Drugs / SW-BIC-213
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT05686161 | Oct → Dec 2022 | — | Stemirna Therapeutics | Unknown | No outcome recorded |
| Phase 3 | NCT05580159 | Oct 2022 → May 2023 | — | Stemirna Therapeutics | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05911087 Comparator | Jun → Jul 2023 | — | Stemirna Therapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SW-BIC-213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911087 ↗ |
| Modality | Messenger RNA (mRNA) | “The mRNA vaccine has demonstrated significant effectiveness in protecting against SARS-CoV-2 during the pandemic” PMID 38169790 ↗ Dec 2023 |
| Route | Intramuscular | “Route of Administration: injection Intramuscular” NCT05580159 ↗ |